Literature DB >> 22855917

Beneficial effects of a high-protein, low-glycemic-load hypocaloric diet in overweight and obese women with polycystic ovary syndrome: a randomized controlled intervention study.

Homeira Hamayeli Mehrabani1, Saghar Salehpour, Zohreh Amiri, Sara Jalali Farahani, Barbara J Meyer, Farideh Tahbaz.   

Abstract

OBJECTIVE: The recommended composition of a hypocaloric diet for obese women with polycystic ovary syndrome (PCOS) is unclear. The aim of this study was to investigate the effects of a high-protein, low-glycemic-load diet compared with a conventional hypocaloric diet on reproductive hormones, inflammatory markers, lipids, glucose, and insulin levels in obese women with PCOS.
METHODS: A total of 60 overweight and obese women with PCOS who did not use insulin-sensitizing agents were recruited and randomly assigned to 1 of the 2 hypocaloric diet groups for a single-blind clinical trial. The groups included a conventional hypocaloric diet (CHCD) (15% of daily energy from protein) and a modified hypocaloric diet (MHCD) with a high-protein, low-glycemic load (30% of daily energy from protein plus low-glycemic-load foods selected from a list) that was prescribed via counseling visits weekly during 12 weeks of study. Anthropometric assessments and biochemical measurements including reproductive hormones, inflammatory factors, lipids, glucose, and insulin were performed on fasting blood samples at baseline and after 12 weeks of dietary intervention.
RESULTS: Weight loss was significant and similar in the 2 groups. Mean of testosterone in the MHCD and CHCD groups decreased from 1.78 ± 0.32 to 1.31 ± 0.26 ng/ml and from 1.51 ± 0.12 to 1.15 ± 0.11 ng/ml, respectively (p < 0.001). Follicle sensitizing hormone (FSH), luteinizing hormone (LH), and blood lipids concentrations were not changed except low-density lipoprotein cholesterol (LDL-C) was reduced by 24.5% ± 12.3% (p < 0.001 for both) after 12 weeks of intervention. MHCD resulted in a significant reduction in insulin level, homeostatic model assessment for insulin resistance (HOMA), and high-sensitivity C- reactive protein (hsCRP) concentration (p < 0.001).
CONCLUSIONS: In this study both hypocaloric diets significantly led to reduced body weight and androgen levels in these two groups of women with PCOS. The combination of high-protein and low-glycemic-load foods in a modified diet caused a significant increase in insulin sensitivity and a decrease in hsCRP level when compared with a conventional diet.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22855917     DOI: 10.1080/07315724.2012.10720017

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  28 in total

1.  Dietary Carbohydrate Intake Does Not Impact Insulin Resistance or Androgens in Healthy, Eumenorrheic Women.

Authors:  Lindsey A Sjaarda; Enrique F Schisterman; Karen C Schliep; Torie Plowden; Shvetha M Zarek; Edwina Yeung; Jean Wactawski-Wende; Sunni L Mumford
Journal:  J Clin Endocrinol Metab       Date:  2015-06-12       Impact factor: 5.958

2.  Effects of a eucaloric reduced-carbohydrate diet on body composition and fat distribution in women with PCOS.

Authors:  Amy M Goss; Paula C Chandler-Laney; Fernando Ovalle; Laura Lee Goree; Ricardo Azziz; Renee A Desmond; G Wright Bates; Barbara A Gower
Journal:  Metabolism       Date:  2014-07-18       Impact factor: 8.694

3.  Effect of orlistat on weight loss, hormonal and metabolic profiles in women with polycystic ovarian syndrome: a randomized double-blind placebo-controlled trial.

Authors:  Ashraf Moini; Mahia Kanani; Ladan Kashani; Reihaneh Hosseini; Ladan Hosseini
Journal:  Endocrine       Date:  2014-10-08       Impact factor: 3.633

4.  Very-low-calorie ketogenic diet (VLCKD) in the management of metabolic diseases: systematic review and consensus statement from the Italian Society of Endocrinology (SIE).

Authors:  M Caprio; M Infante; E Moriconi; A Armani; A Fabbri; G Mantovani; S Mariani; C Lubrano; E Poggiogalle; S Migliaccio; L M Donini; S Basciani; A Cignarelli; E Conte; G Ceccarini; F Bogazzi; L Cimino; R A Condorelli; S La Vignera; A E Calogero; A Gambineri; L Vignozzi; F Prodam; G Aimaretti; G Linsalata; S Buralli; F Monzani; A Aversa; R Vettor; F Santini; P Vitti; L Gnessi; U Pagotto; F Giorgino; A Colao; A Lenzi
Journal:  J Endocrinol Invest       Date:  2019-05-20       Impact factor: 4.256

5.  The impact of protein quantity during energy restriction on genome-wide gene expression in adipose tissue of obese humans.

Authors:  I P G Van Bussel; E M P Backx; C P G M De Groot; M Tieland; M Müller; L A Afman
Journal:  Int J Obes (Lond)       Date:  2017-03-24       Impact factor: 5.095

Review 6.  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.

Authors:  Dimitrios Panidis; Konstantinos Tziomalos; Efstathios Papadakis; Christos Vosnakis; Panagiotis Chatzis; Ilias Katsikis
Journal:  Endocrine       Date:  2013-04-27       Impact factor: 3.633

7.  Combined androgen excess and Western-style diet accelerates adipose tissue dysfunction in young adult, female nonhuman primates.

Authors:  Oleg Varlamov; Cecily V Bishop; Mithila Handu; Diana Takahashi; Sathya Srinivasan; Ashley White; Charles T Roberts
Journal:  Hum Reprod       Date:  2017-09-01       Impact factor: 6.918

Review 8.  The role of glycemic index and glycemic load in cardiovascular disease and its risk factors: a review of the recent literature.

Authors:  Arash Mirrahimi; Laura Chiavaroli; Korbua Srichaikul; Livia S A Augustin; John L Sievenpiper; Cyril W C Kendall; David J A Jenkins
Journal:  Curr Atheroscler Rep       Date:  2014-01       Impact factor: 5.113

9.  Lifestyle changes in women with polycystic ovary syndrome.

Authors:  Siew S Lim; Samantha K Hutchison; Emer Van Ryswyk; Robert J Norman; Helena J Teede; Lisa J Moran
Journal:  Cochrane Database Syst Rev       Date:  2019-03-28

10.  Women's Health Endocrinology Update.

Authors:  Ekta Kapoor; Stephanie S Faubion; Juliana M Kling
Journal:  J Womens Health (Larchmt)       Date:  2021-12-06       Impact factor: 2.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.